Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Personalized combo therapy aims to beat head and neck cancer

NCT ID NCT02128906

First seen Apr 25, 2026 · Last updated Apr 29, 2026 · Updated 1 time

Summary

This study tests which of two chemotherapy combinations works better when given with radiation for advanced head and neck cancer. About 120 participants will receive either cisplatin or a mix of docetaxel and cetuximab. Researchers will also check if a tumor marker called ERCC1 helps predict which treatment is best for each person.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UPMC Hillman Cancer Center - Radiation Oncology

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.